Clinical trial
A Phase I Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
NCT06518551 is registered in ClinicalTrials.gov with Omar Nadeem, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Omar Nadeem, MD
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 1, 2024
- Completion date
- December 31, 2034
- Enrollment
- 49 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
multiple myeloma, myeloma, refractory multiple myeloma